查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609134

奈米醫學市場：按分子類型、形態、應用和適應症分類 - 全球預測 2025-2030

Nanomedicine Market by Molecule Type (Nanodevices, Nanoparticles, Nanoshells), Modality (Diagnostics, Treatment), Application, Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年奈米醫學市場價值為2062.5億美元，預計到2024年將達到2273.7億美元，複合年成長率為10.91%，到2030年將達到4258.8億美元。

奈米醫學奈米技術用於開發分子層面的醫療應用工具和治療方法。這些包括藥物傳輸、診斷、影像和再生醫學。對奈米醫學的需求源於對副作用較少的標靶治療的需求，以解決使用傳統方法無法有效治療的複雜病症。其應用範圍廣泛，為先前未滿足的醫療需求提供解決方案，包括提高癌症治療的精確度、提高藥物溶解度和組織工程。主要最終用途領域包括癌症治療、心血管和神經系統疾病以及感染疾病。

主要市場統計
基準年[2023] 2062.5億美元
預測年份 [2024] 2273.7億美元
預測年份 [2030] 4258.8億美元
複合年成長率（%） 10.91%

該市場是由技術創新、慢性病的增加以及政府和私營部門研究投資的增加所推動的。奈米技術的快速發展以及製藥公司和研究機構之間的合作也極為重要。然而，研究成本上升、監管障礙和潛在毒性問題等挑戰正在阻礙成長。嚴格的核准流程和研發的複雜性也是主要障礙。

市場上的機會已經成熟，可以根據個人的基因特徵客製化個人化醫療。生物分解性奈米顆粒的探索以及透過超靈敏生物感測器增強診斷能力呈現出寶貴的前景。為了利用這些優勢，促進學術界和工業界之間的合作並確保轉化研究的資金非常重要。另一個有前景的領域是開發多功能奈米醫學系統，將治療和診斷功能整合到一個平台中。

為了實現業務成長，您應該專注於醫療保健需求和基礎設施不斷成長的地區，例如亞太地區和拉丁美洲。創新格局應優先考慮安全性和有效性，並納入以患者為中心的策略。總體而言，市場格局正在擴大，但應對複雜的監管格局和技術需求需要戰略遠見和適應性創新。

市場動態：揭示快速發展的奈米醫學市場的關鍵市場洞察

供需的動態交互作用正在改變奈米醫學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病的流行和有效治療的需求
    • 利用奈米醫學技術進行個人化醫療
    • 在體外診斷和體內成像的應用
  • 市場限制因素
    • 奈米藥物的開發和商業化成本高昂
  • 市場機會
    • 新型奈米醫學開發策略聯盟
    • 奈米醫學研究和開發的有利資金狀況
  • 市場挑戰
    • 可用的臨床證據有限

波特五力：駕馭奈米醫學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解奈米醫學市場的外部影響

外部宏觀環境因素在塑造奈米醫學市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解奈米醫學市場的競爭狀況

對奈米醫學市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣奈米醫學市場供應商績效評估

FPNV定位矩陣是評估奈米醫學市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了奈米醫學市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，奈米醫學市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和有效治療的需求
      • 奈米醫學技術在個人化醫療的應用
      • 在體外診斷和體內成像的應用
    • 抑制因素
      • 奈米藥物的開發和商業化成本高昂
    • 機會
      • 奈米醫學新開發策略聯盟
      • 奈米醫學研究和開發的有利資金籌措環境
    • 任務
      • 臨床證據有限
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以分子類型分類的奈米醫學市場

  • 奈米裝置
  • 奈米粒子
    • 樹狀聚合物
    • 水凝膠奈米顆粒
    • 無機奈米粒子
    • 脂質體
    • 金屬和金屬氧化物奈米粒子
    • 聚合物和聚合物藥物綴合物
  • 奈米殼
  • 奈米管

第7章 奈米醫學市場：依形式

  • 診斷
  • 治療

第8章奈米醫學市場：依應用分類

  • 診斷影像
  • 藥物輸送
  • 植入
  • 再生醫學
  • 疫苗

第9章 奈米醫學市場（按適應症）

  • 臨床心臟病學
  • 臨床腫瘤學
  • 免疫學
  • 感染疾病
  • 神經病學
  • 眼科
  • 整形外科
  • 泌尿系統

第10章美洲奈米醫學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區奈米醫學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的奈米醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AMAG Pharmaceuticals, Inc.
  • Amgen Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bausch Health Companies Inc.
  • Bayer Healthcare
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eisai Co Ltd
  • F. Hoffmann-La Roche AG
  • Galen Ltd
  • General Electric Company
  • Gilead Sciences, Inc.
  • Ipsen SA
  • Jazz Pharmaceuticals plc
  • Lantheus Holdings, Inc.
  • Leadient BioSciences Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Nano spectra Biosciences, Inc.
  • Novo Nordisk A/S
  • OSARTIS GmbH
  • Pacira BioSciences Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Taiwan Liposome Company, Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Ltd.
  • UCB SA
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-C002B1C9955D

The Nanomedicine Market was valued at USD 206.25 billion in 2023, expected to reach USD 227.37 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 425.88 billion by 2030.

Nanomedicine harnesses nanotechnology's advancements in developing tools and treatments at the molecular level for medical applications. It covers drug delivery, diagnostics, imaging, and regenerative medicine. The necessity of nanomedicine arises from the demand for targeted therapies with minimal side effects, addressing complex conditions that traditional methods can't effectively treat. Its application is vast, offering enhanced precision in cancer therapy, improved drug solubility, and tissue engineering, providing solutions for previously unmet medical needs. Key end-use areas include cancer treatment, cardiovascular and neurological disorders, and infectious diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 206.25 billion
Estimated Year [2024] USD 227.37 billion
Forecast Year [2030] USD 425.88 billion
CAGR (%) 10.91%

The market is driven by technological innovations, the rising prevalence of chronic diseases, and increasing government and private sector investments in research. Rapid advancements in nanotechnology and collaborations between pharmaceuticals and research institutions are also pivotal. However, challenges such as high costs of research, regulatory hurdles, and potential toxicity issues impede growth. The strict approval process and R&D complexity also pose significant barriers.

Opportunities within the market are ripe in personalized medicine, where nanomedicine can be tailored to individual genetic profiles. Exploring biodegradable nanoparticles and enhancing diagnostic capabilities with ultra-sensitive biosensors present valuable prospects. To capitalize on these, fostering collaborations between academia and industry and securing funding for translational research are crucial. Another promising area is the development of multifunctional nanomedicine systems that combine therapeutic and diagnostic functions into a single platform.

For business growth, focus should be on regions with growing healthcare needs and infrastructure, like Asia-Pacific and Latin America. The innovation landscape should prioritize safety and efficacy, embedding patient-centric strategies. Overall, while the nanomedicine market is poised for expansive growth, navigating its complex regulatory landscape and technological demands will require strategic foresight and adaptive innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Nanomedicine Market

The Nanomedicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for efficient treatment
    • Utilization of nanomedicine technology for personalized medicine
    • Applications in vitro diagnostics and in vivo imaging
  • Market Restraints
    • High cost of development and commercialization of nanomedicine
  • Market Opportunities
    • Strategic alliances for development of novel nanomedicine
    • Favorable funding landscape for research and development of nanomedicine
  • Market Challenges
    • Limited availability of clinical evidence

Porter's Five Forces: A Strategic Tool for Navigating the Nanomedicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Nanomedicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Nanomedicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Nanomedicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Nanomedicine Market

A detailed market share analysis in the Nanomedicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Nanomedicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Nanomedicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Nanomedicine Market

A strategic analysis of the Nanomedicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Nanomedicine Market, highlighting leading vendors and their innovative profiles. These include AMAG Pharmaceuticals, Inc., Amgen Inc., Arrowhead Pharmaceuticals, Inc., Bausch Health Companies Inc., Bayer Healthcare, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eisai Co Ltd, F. Hoffmann-La Roche AG, Galen Ltd, General Electric Company, Gilead Sciences, Inc., Ipsen SA, Jazz Pharmaceuticals plc, Lantheus Holdings, Inc., Leadient BioSciences Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Nano spectra Biosciences, Inc., Novo Nordisk A/S, OSARTIS GmbH, Pacira BioSciences Inc., Pfizer Inc., Sanofi S.A., Taiwan Liposome Company, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Ltd., UCB SA, and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Nanomedicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Nanodevices, Nanoparticles, Nanoshells, and Nanotubes. The Nanoparticles is further studied across Dendrimers, Hydrogel Nanoparticles, Inorganic Nanoparticles, Liposomes, Metal & Metal Oxide Nanoparticles, and Polymers & Polymer Drug Conjugates.
  • Based on Modality, market is studied across Diagnostics and Treatment.
  • Based on Application, market is studied across Diagnostic Imaging, Drug Delivery, Implants, Regenerative Medicine, and Vaccines.
  • Based on Indication, market is studied across Clinical Cardiology, Clinical Oncology, Immunology, Infectious Diseases, Neurology, Ophthalmology, Orthopedics, and Urology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for efficient treatment
      • 5.1.1.2. Utilization of nanomedicine technology for personalized medicine
      • 5.1.1.3. Applications in vitro diagnostics and in vivo imaging
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development and commercialization of nanomedicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic alliances for development of novel nanomedicine
      • 5.1.3.2. Favorable funding landscape for research and development of nanomedicine
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of clinical evidence
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Nanomedicine Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Nanodevices
  • 6.3. Nanoparticles
    • 6.3.1. Dendrimers
    • 6.3.2. Hydrogel Nanoparticles
    • 6.3.3. Inorganic Nanoparticles
    • 6.3.4. Liposomes
    • 6.3.5. Metal & Metal Oxide Nanoparticles
    • 6.3.6. Polymers & Polymer Drug Conjugates
  • 6.4. Nanoshells
  • 6.5. Nanotubes

7. Nanomedicine Market, by Modality

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Treatment

8. Nanomedicine Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic Imaging
  • 8.3. Drug Delivery
  • 8.4. Implants
  • 8.5. Regenerative Medicine
  • 8.6. Vaccines

9. Nanomedicine Market, by Indication

  • 9.1. Introduction
  • 9.2. Clinical Cardiology
  • 9.3. Clinical Oncology
  • 9.4. Immunology
  • 9.5. Infectious Diseases
  • 9.6. Neurology
  • 9.7. Ophthalmology
  • 9.8. Orthopedics
  • 9.9. Urology

10. Americas Nanomedicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Nanomedicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Nanomedicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AMAG Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. Arrowhead Pharmaceuticals, Inc.
  • 4. Bausch Health Companies Inc.
  • 5. Bayer Healthcare
  • 6. Biogen Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Celgene Corporation
  • 9. Eisai Co Ltd
  • 10. F. Hoffmann-La Roche AG
  • 11. Galen Ltd
  • 12. General Electric Company
  • 13. Gilead Sciences, Inc.
  • 14. Ipsen SA
  • 15. Jazz Pharmaceuticals plc
  • 16. Lantheus Holdings, Inc.
  • 17. Leadient BioSciences Inc.
  • 18. Mallinckrodt Pharmaceuticals
  • 19. Merck & Co., Inc.
  • 20. Nano spectra Biosciences, Inc.
  • 21. Novo Nordisk A/S
  • 22. OSARTIS GmbH
  • 23. Pacira BioSciences Inc.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Taiwan Liposome Company, Ltd.
  • 27. Takeda Pharmaceutical Company Limited
  • 28. Teva Pharmaceuticals Ltd.
  • 29. UCB SA
  • 30. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. NANOMEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. NANOMEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NANOMEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NANOMEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NANOMEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NANOMEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NANOMEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NANOMEDICINE MARKET SIZE, BY NANODEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NANOMEDICINE MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NANOMEDICINE MARKET SIZE, BY HYDROGEL NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NANOMEDICINE MARKET SIZE, BY INORGANIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NANOMEDICINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NANOMEDICINE MARKET SIZE, BY METAL & METAL OXIDE NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NANOMEDICINE MARKET SIZE, BY POLYMERS & POLYMER DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOSHELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NANOMEDICINE MARKET SIZE, BY NANOTUBES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NANOMEDICINE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NANOMEDICINE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NANOMEDICINE MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NANOMEDICINE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NANOMEDICINE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NANOMEDICINE MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NANOMEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NANOMEDICINE MARKET SIZE, BY CLINICAL CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NANOMEDICINE MARKET SIZE, BY CLINICAL ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NANOMEDICINE MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NANOMEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NANOMEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NANOMEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NANOMEDICINE MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NANOMEDICINE MARKET SIZE, BY UROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NANOMEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. TAIWAN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. THAILAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. VIETNAM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NANOMEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. DENMARK NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EGYPT NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. FINLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. FRANCE NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. GERMANY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. ISRAEL NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. ITALY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NETHERLANDS NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. NIGERIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. NORWAY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. POLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. QATAR NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. RUSSIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SAUDI ARABIA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SPAIN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. SWEDEN NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SWITZERLAND NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. TURKEY NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED ARAB EMIRATES NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NANOMEDICINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 246. NANOMEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 247. NANOMEDICINE MARKET, FPNV POSITIONING MATRIX, 2023